NICE rejects extended use of Alimta (Eli Lilly) in NSCLC
NICE (The National Institute of Health and Clinical Excellence) has not recommended Alimta (pemetrexed) from Eli Lilly for use as a maintenance treatment for Non-Small-Cell Lung Cancer (NSCLC) following induction therapy with pemetrexed and cisplatin in its preliminary guidance.
NICE had given its recommendation to the drug as a first line treatment option for NSCLC and as a maintenance treatment option following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. But NICE has not extended this to NSCLC maintenance treatment after pemetrexed and cisplatin use.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins